Last reviewed · How we verify
Niacin deficiency — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Nicorette | NICOTINE | Sanofi | Cholinergic Nicotinic Agonist [EPC] | Neuronal acetylcholine receptor; alpha4/beta2 | 1991-01-01 | |
| Infuvite Adult | Nicotinamide | Pfizer | Standardized Chemical Allergen [EPC] | NAD-dependent protein deacetylase sirtuin-2 | 1953-01-01 | |
| Myoinositol | Myoinositol | University of Colorado, Denver |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 3 drugs in Niacin deficiency
- Pfizer · 1 drug in Niacin deficiency
- Sanofi · 1 drug in Niacin deficiency
- University of Colorado, Denver · 1 drug in Niacin deficiency
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Niacin deficiency:
- Niacin deficiency treatment updates — RSS
- Niacin deficiency treatment updates — Atom
- Niacin deficiency treatment updates — JSON
Cite this brief
Drug Landscape (2026). Niacin deficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/niacin-deficiency. Accessed 2026-06-10.
Related
- Niacin deficiency full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing